Silver Book Fact

Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.

Wagner E, Sandhu N, Newton K, McCulloch D, et al. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA. 2001; 285(2): 182-189. http://jama.ama-assn.org/cgi/content/abstract/285/2/182

Reference

Title
Effect of Improved Glycemic Control on Health Care Costs and Utilization
Publication
JAMA
Publisher
JAMA
Publication Date
2001
Authors
Wagner E, Sandhu N, Newton K, McCulloch D, et al
Volume & Issue
Volume 285, Issue 2
Pages
182-189
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.